EUVIMEDDescubrir EUVIMED
Crossref

The NRF2 readout beyond genotyping †

Yukako Suzuki, Maolin Ge iD

The Journal of Pathology · 2026-07 · 269 (3) · 265-267

DOI: 10.1002/path.70061 ↗

At a glance

Journal article in The Journal of Pathology, published online on 2026-04-07. Written by Yukako Suzuki and 1 co-authors. Institution: Krantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center, Charlestown, MA, USA. Major MEDLINE topics: Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, NF-E2-Related Factor 2. 13 references. Funded by: JST SPRING, Yamagata Prefectural Government and Tsuruoka City, NCI NIH HHS.

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Non‐small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, and many patients derive limited benefit from current systemic therapies. Until now, clinical and translational efforts have largely focused on recurrent genomic alterations in the Kelch‐like ECH‐associated protein 1–nuclear factor erythroid 2‐related factor 2 (NRF2) axis, yet mutation status alone often fails to capture the biological heterogeneity and context dependence of NRF2 pathway dysregulation. In recent years, growing evidence has highlighted the NRF2 activation state as a clinically relevant feature that better reflects resistance phenotypes and therapeutic liabilities than genotyping alone. The recent work by Härkönen et al , published in The Journal of Pathology , suggests that anchoring genotype to phenotype using functional readouts is essential for defining NRF2 hyperactivity. Mechanistic studies further suggest that NRF2 hyperactivity can impose context‐dependent metabolic liabilities. We discuss the next steps towards clinical translation, including prospective NRF2 activation‐state stratification, integration of immune context for immunotherapy, and biomarker evaluation of redox and metabolic combinations based on NRF2‐associated vulnerabilities. © 2026 The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Biomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsNF-E2-Related Factor 2AnimalsHumansGenotypeMutationPhenotypeSignal Transduction

Author keywords

KEAP1NRF2 activationNSCLCctDNAimmunotherapyliquid biopsymetabolic vulnerability

Substances

Biomarkers, TumorNF-E2-Related Factor 2NFE2L2 protein, human

Authors and institutions

  • Krantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center, Charlestown, MA, USA.
  • Institute for Advanced Biosciences, Keio University, Tsuruoka, Japan.
  • Systems Biology Program, Graduate School of Media and Governance, Keio University, Fujisawa, Japan.

ORCID profiles: Maolin Ge

Funding

  • JST SPRING
  • Yamagata Prefectural Government and Tsuruoka City
  • NCI NIH HHS
  • National Cancer Institute

Cite

APA

Suzuki, Y., & Ge, M. (2026). The NRF2 readout beyond genotyping †. The Journal of Pathology, 269(3), 265-267. https://doi.org/10.1002/path.70061

Vancouver

Suzuki Y, Ge M. The NRF2 readout beyond genotyping †. The Journal of Pathology. 2026;269(3):265-267. doi:10.1002/path.70061

BibTeX
@article{Suzuki2026,
  author = {Suzuki, Yukako and Ge, Maolin},
  title = {The NRF2 readout beyond genotyping †},
  journal = {The Journal of Pathology},
  year = {2026},
  volume = {269},
  number = {3},
  pages = {265--267},
  doi = {10.1002/path.70061}
}
Start for free →